The Associated Press reported on the 7th (local time) that South Africa (South Africa) has decided FX마진거래
to suspend the use of the AstraZeneca and Oxford co-development vaccine, which was scheduled to begin vaccination in the middle of this month. The decision to suspend the use of the vaccine is the second after Switzerland. South Africa's decision is particularly due to studies showing that the vaccine is not effective against mutant viruses in South Africa's. As a result, controversy over the efficacy of the AstraZeneca vaccine is expected to spread further.
South Africa's Ministry of Health said on the same day, "We will suspend the vaccination of AstraZeneca for the time being, reflecting the study that the effectiveness of the AstraZeneca vaccine is limited for the mutant virus in Korea (South Africa) South Africa's Ministry of Health said researchers at Oxford University and Bitbatersrand University in South Africa tested 2026 people the previous day and were informed that the vaccine did not effectively prevent the mutant virus in South Africa.
Of the 2026 people who participated in the study, 19 were infected with South African mutations, and a comparative test of the 19 showed that the vaccine for South African mutations was about 10 percent effective, said Sabir Madi, dean of Wittbatersrand University Medical School. The World Health Organization (WHO) believes that vaccines have to be more than 50 percent effective to prevent them.
As a result, the South African government decided to keep the 1 million doses of AstraZeneca vaccine delivered on the 1st until additional data came out and reviewed whether to use it again. Instead, he said he would make efforts to supply the Johnson & Johnson vaccine for the time being. AstraZeneca and Oxford University have announced that they will develop and release next-generation vaccines that can prevent mutant coronavirus by this fall.